Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 7/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402801 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| Guanidine SCHEMBL7165528 | 0.90 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| Guanidine SCHEMBL7165534 | 0.90 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL3893886 | 0.86 | AKR1C3 (0.68) | CYP2C9AKR1C3APEX1MAPT | |
| SCHEMBL31666241 | 0.86 | AKR1C3 (0.68) | CYP2C9AKR1C3APEX1MAPT | |
| SCHEMBL8746671 | 0.86 | AKR1C3 (0.68) | CYP2C9AKR1C3APEX1MAPT | |
| SCHEMBL3597473 | 0.82 | AKR1C3 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL8324244 | 0.81 | CYP1A2 (0.73) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL6462299 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL3400093 | 0.80 | TRPA1 (0.62) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| EP-3517571-A1 | (METH)ACRYLIC COPOLYMER, RESIN COMPOSITION, MOLDED BODY OF SAME, AND METHOD FOR PRODUCING MOLDED BODY | Mitsubishi Gas Chemical Company, Inc. (JP) | 2019-07-31 | — | — | EP | disclosed |
| EP-3443959-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3079685-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-28 | — | — | EP | disclosed |
| EP-3079686-B1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-10-24 | — | — | EP | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-2861571-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | Bio-Pharm Solutions Co., Ltd. (KR) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013187727-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-12-19 | — | — | WO | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| EP-2249820-A1 | TRPA1 ANTAGONISTS | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009089082-A1 | TRPA1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176883-A1 | TRPA1 Antagonists | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-6504057-B2 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT | 2002-09-05 | — | — | US | disclosed |
| US-20010020042-A1 | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176883-A1 | TRPA1 Antagonists | TRPA1, TRPV1, TRPV3 | CYP1A2 1231/4885CYP3A4 2452/4885CYP2C9 2036/4885 |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | CYP1A2 784/4885CYP3A4 1449/4885CYP2C9 1262/4885 |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | TNNI3, SLC5A1, TNNC1 | CYP1A2 3517/4885CYP3A4 3395/4885CYP2C9 2709/4885 |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | CYP1A2 1915/4885CYP3A4 2956/4885CYP2C9 1325/4885 |
| US-20010020042-A1 | Cardiovascular disorders | SLC5A1, SLC9A1, SLC28A1 | CYP1A2 946/4885CYP3A4 1663/4885CYP2C9 539/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | CYP1A2 1915/4885CYP3A4 2956/4885CYP2C9 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.